Halozyme and Argenx Expand Collaboration
Halozyme Therapeutics has expanded its global collaboration with argenx SE, granting argenx exclusive access to Halozyme's ENHANZE drug-delivery technology for two additional therapeutic targets.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
4 results loaded, newest first. End of these results.
Halozyme Therapeutics Expands Licensing Agreement With Argenx
Halozyme Therapeutics is expanding its partnership with Argenx, granting the immunology company access to its Enhanze drug delivery technology with two additional exclusive targets.
Halozyme Therapeutics Expands Licensing Agreement With Argenx
By Elias Schisgall Halozyme Therapeutics is expanding its partnership with Argenx, allowing the immunology company access to its Enhanze drug delivery technology with two additional exclusive targets. Halozyme said Tuesday that its global collaboration and licensing agreement with Argenx now covers the use of Enhanze f
Halozyme Expands argenx Collaboration for Subcutaneous Formulations
Halozyme announced an expansion of its global collaboration and license agreement with argenx. This expansion will support the development of subcutaneous formulations for two additional exclusive targets using Halozyme's ENHANZE® Technology.